Administrative Organization
|
|
- Juniper Hancock
- 8 years ago
- Views:
Transcription
1 PATIENT DATA AND PATIENT REGISTRIES IN CENTRAL & EASTERN EUROPE Patient Registries as an Opportunity in Bosnia Herzegovina for Access to Medicines Speaker: Tarik Catic, MScPharm, PhD (c), President, ISPOR Bosnia Herzegovina Chapter Health Economics and Pharmacoeconomics Consultant Sarajevo, Bosnia Herzegovina ISPOR 16th Annual European Congress 2 6 November 2013 Dublin, Ireland Administrative Organization State level Bosnia and Herzegovina Entity level Federation of Bosnia and Herzegovina Republic of Srpska Brcko District Cantonal /regional level 10 Cantons 4 Regions
2 Health Care/Medicines Financing Federation of Bosnia & Herzegovina Federal Health Insurance Fund Cantonal Insurance Fund(s) Hospital Budgets Republic of Srpska Health Insurance Fund Hospital Budgets Brcko District Health Insurance Fund Hospital Budgets Pharmaceutical Key Stakeholders in B&H Institution ALIMSBH* Ministry of Civilan Affairs Responsibilities Marketing approval for medicines Pricing control (IRP) State Federation of B&H Republicof Srpska, B&H Coordinative role among entities and international organizations *Agency for medicines and medical devices of Bosnia and Herzegovina Federal Ministry of Health / Cantonal Minstries of Health FMoH Adopt Federal list of Essential medicines and set price 1. List A 100% RB and obligatory for Cantonal HIFs 2. List B different copayment levels and optional to Cantonal HIFs Adopt list of expensive drugs (CTx, MS, biologics etc) Federal Health Insurance Fund / Cantonal Insurance Fund Responisble for financing of Expensive drugs listed by Federal MoH Tender procurement procedure Health insurance fund Set list of mediciens used in primary health care Set list of expensive medicines (CTx, MS, biologics etc) Set prices and conduct tender procurement for expensive medicines Brcko District Health Insurance Fundn Set list of medicines used in primary health care and hospital medicine list
3 Expensive Medicines RB Process Federation of Bosnia & Herzegovina Republic of Srpska Step 1 Ministry of Health Inclusion into list of CTx Base for tender LOTs by INN/presentation Inclusion into list of CTx HIF / Commission for CTx Step 2 Federal HIF Tender (quantity and specific conditions specified) Tender (quantity and specific conditions defined; bi yearly tender) HIF Step 3 Federal HIF Orders by Hospitals (bi monthly) Orders from Hospitals collected by National Coordinator (monthly) HIF Deadlines are not defined in legislation In practice months Access to Medicines in Bosnia and Herzegovina Innovative Products Both entities adopt list of expensive medicines CTx Biologics Innovative medicines There is no orphan drug budget/list
4 Access to Medicines in Bosnia and Herzegovina Innovative Products Limitted number of innovative products is available either included into RB list or financed through the projects Market access for these drugs is delayed and mostly financed through projects and special secret agreements between HIFs and industry Restricted number of patients (patient cap?) Assigned budget for specific drug/indication (budget cap?) Special conditions/approvals by commissions appointed by HIF board (patient named programs?) Access to Medicines in Bosnia and Herzegovina Innovative Products CTx lists in FB&H and RS innovative products (biologics) imatinib rituximab trastuzumab bevacizumab erlotinib Federation of B&H* Republic of Srpska** * Products introduced into the list under special conditions and approval for therapy on patient base by special medical commission after medical documentation evaluation ** Products fully reimbursed Projects are highly valuable in MA strategy according to previous experiences (Federation of B&H) srpske.org
5 Patient Data and Registries (Focus on Federation of B&H) Legal framework Recently established law on health care records (2012) Ordinance on procedure and criteria for introduction of medicines into Federal list of medicines Responsible institutions Institute of Public Health Mostly dealing with epidemiology data Not on patient level Health Insurance Fund(s) Keep records on insured persons Patient records at primary care level and clinical centers/hospitals Keep records on treated patients All of these records are not used for outcomes research or published Lack of data analysis and centralisation of the system A lot of worthless paper work Patient Data and Registries (Focus on Federation of B&H) Law on health care records Defines Patient registries, patient data that should be collected and handling of data (confidentiality) and all evidences that are obligatory in health care eg. Record on visits to physicians and health services provided Record of special diseases like cancer, diabetes, CKD Record related to health insurance Ordinance on procedure and criteria for introduction of medicines into Federal list of medicines Patented (originator) drug manufacturer is required to establish proces (registry; patient data collection and analysis) to follow up proper use of drug, therapeutic outcomes, interactions and adverese eventss in 2 year period after drug is introduced into the List Good basis for establishing patient data practice and possible outcome research
6 Positive Movement Example 1 Introduction to e health care ID Launched in September 2013 in Canton Sarajevo as a pilot project Implemented by Cantonal HIF and MoH Patient data (disease history, treatments, lab tests, etc) stored and accessible at any health care center Possibility for patient outcomes research? Positive Movement Example 2 Disease registry Diabetes patient registry Project lead by ISPOR BH industry sposnored (launched in May 2013) Pilot project in one canton in Federation of B&H Disease registry following epidemiology data, therapy outcomes and related cost cost of diabetes study
7 Positive Movement Example 3 THE RENAL REGISTRY FOR BOSNIA AND HERZEGOVINA The Society for Nephrology, Dialysis, and Transplantation in Bosnia and Herzegovina has formed the Renal Registry and started gathering data in 1999 Data collected from all of the 20 centers in Bosnia and Herzegovina following the European renal registry standards Patient surveys includes groups of questions about the center itself (size, equipment, staff, water treatment), about the distribution of patients according to sex, age, primal renal disease, length and model of treatment, mortality, and about the number of kidney transplantations. Annual reports renal register The Use of Patient Data to Improve Access to Medicines Real World Evidence Patient registries, whether disease based or product focused, can provide invaluable data about the natural history of a disease under standard care practices and/or the safety and effectiveness of a product. These data can then be presented as evidence to: Meet safety requirements and manage benefits and risks Provide evidence to meet evolving coverage or reimbursement requirements Generate scientific evidence and publications Develop treatment guidelines Demonstrate good product stewardship
8 The Use of Patient Data to Improve Access to Medicines What can we get from patient registry? Generate knowledge and evidence (scientific presentations and publications) Demonstrate effectiveness or comparative effectiveness in different populations Meet post marketing commitments Generate evidence for coverage Monitor safety Manage risks and benefits Generate data for new indications or label extensions Change behavior Improve quality of care Prove product value through economic or quality of life benefits Bring scientific information to stakeholders sooner Enhance the practice of personalized medicine The Use of Patient Data to Improve Access to Medicines Conclusion There is a legal framework for introduction of patient registries Possibilities to establish new apporach for reimbursement of new (innovative and expensive drugs) Different types of Risk Sharing Agreements /Schemes Performance based RSS Payback models Restricted population Conditional reimbursement Implementation of new RB approach can accelerate patient acces to new drugs, develop partnership between authorities and industry Collection of valuable data for scientific purposes
DECISION. Single Registry of Legal Entities Transaction Accounts in. Bosnia and Herzegovina. Article 1
Herein we put out of force the revised text of the Decision on the Single Registry of Transaction Accounts in Bosnia and Herzegovina, 101-977/10 as of May 27, 2010 (published in Offical Gazette of BH,
More informationHealth Care Services
Abdulaziz H Al Saggabi, BSc, MSc, PharmD, Director, Drug Policy & Economics Center National Guard Health Affair & President ISPOR Saudi Arabia Chapter Presentation Outline y Background of Saudi Arabia
More informationHEALTH CARE DATA IN QATAR
HEALTH CARE DATA IN QATAR Daoud Al-Badriyeh, PhD President, ISPOR Qatar Chapter and Assistant Professor of Pharmacoeconomics College of Pharmacy, Qatar University Doha, Qatar Health Care Data The problem:
More informationEnd Stage Renal Disease (ESRD)
End Stage Renal Disease (ESRD) AN OVERVIEW OF ESRD, TREATMENT COSTS & COVERAGE WSHIP Board Meeting January 14, 2015 Lisa Matthews and Sharon Becker 1 Kidney Disease Facts & Figures 1 in 10 people have
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More informationSPEAKER BIOGRAPHICAL INFORMATION
SPEAKER BIOGRAPHICAL INFORMATION Madeleine R. Valera MD, MScIH (Heidelberg) Dr. Valera is a senior health care service professional with over 20 years of professional expertise in Health Financing and
More informationRisk-sharing Agreements: Country Experiences and Challenges
Risk-sharing Agreements: Country Experiences and Challenges 101/2014 INSEAD Healthcare Management Initiative www.insead.edu/hmi hmi@insead.edu Written by Ridhima Aggarwal, The Salmon and Rameau Research
More informationAnalysis of Hospital Pharmaceuticals
Danish Ministry of Health and Prevention Analysis of Hospital Pharmaceuticals Country Report - Germany March 2009 COWI A/S Parallelvej 2 DK-2800 Kongens Lyngby Denmark Tel +45 45 97 22 11 Fax +45 45 97
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationOPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS
OPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS April 27 29, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL MEETING OF ISMPP 1 ORGANIZED HEALTHCARE
More informationEmergence of Compassionate Use programmes
Emergence of Compassionate Use programmes Rosanna Melchior, PharmD, MS IDRAC, Thomson Scientific Overview What is compassionate use (CU) Overview of CU in Europe Authorities and Sponsors Roles and Responsibilities
More informationGlobal Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3070277/ Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of
More informationGlobal Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3070278/ Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of
More informationGlobal Haemophilia Epidemiology and Patient Flow Analysis - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3070298/ Global Haemophilia Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of its Haemophilia
More informationJoint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
More informationGeneric substitution of prescription drugs
Generic substitution of prescription drugs Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (2)2003 Author(s): Ilmo Keskimäki and Lauri Vuorenkoski
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationAbt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services
Abt Associates Inc. Abt Associates Clinical Trials Comprehensive clinical research services Providing a wide range of clinical research services Abt Associates Clinical Trials (AACT) is dedicated to providing
More informationCommercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Brochure More information from http://www.researchandmarkets.com/reports/1314569/ Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive
More informationHow To Improve Health Care In Danesmark
Der da nische Markt der Gesundheitswirtschaft: Struktur, Chancen und rechtliche Rahmenbedingungen Malene Nørby Nielsen International Marketing Manager Healthcare DENMARK 28-11-2014 1 Healthcare DENMARK
More informationRichard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS
More informationCommonwealth Coordinated Care Enrollment Application Form
Keep a copy of this form for your records Commonwealth Coordinated Care Enrollment Application Form To join a Commonwealth Coordinated Care plan, you must have Medicare Part A, Medicare Part B, and Medicaid.
More informationDialysis Patients' Bill of Rights and Responsibilities
Dialysis Patients' Bill of Rights and Responsibilities PATIENTS Rights Quality Care Information Individual Treatment Privacy and Confidentiality Services Without Discrimination Treatment Options Kidney
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More informationDoctor of Pharmacy/Master of Public Health Joint Degree Program
Rationale Doctor of Pharmacy/Master of Public Health Joint Degree Program The Master of Public Health (MPH) program is designed to prepare students to become effective leaders, practitioners, researchers,
More informationThe National Health Insurance Scheme in Ghana: Best Practices. Regional Conference on Social Health Protection in East African Community
The National Health Insurance Scheme in Ghana: Best Practices Regional Conference on Social Health Protection in East African Community Dr. Lydia Dsane-Selby Director, Clinical Audit National Health Insurance
More informationConsultation: Two proposals for registered nurse prescribing
Consultation: Two proposals for registered nurse prescribing Submission Form Please read and refer to the consultation document Two proposals for registered nurse prescribing available on the Nursing Council
More informationCorMedix, Inc. (CRMD) - Product Pipeline Analysis
Brochure More information from http://www.researchandmarkets.com/reports/1595808/ Description: Summary CorMedix, Inc. (CorMedix) is a pharmaceutical company, based in the US. It develops and seeks to commercialize
More informationAvastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationMedicare Shared Savings Program (ASN) and the kidney Disease Prevention Project
December 3, 2010 Donald Berwick, MD Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Room 445-G, Hubert H. Humphrey Building 200 Independence Avenue, SW
More informationPrinciples for application of international reference pricing systems
Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While
More informationThe Socio-economic Environment of Greece
HTA DEVELOPMENTS IN THE CENTRAL AND EASTERN EUROPEAN REGION: LOCK, STOCK & BARREL IN CHALLENGING TIMES The experience of GREECE Mary Geitona, MSc, Ph.D President ISPOR Greece Chapter As. Professor, University
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationThe registry of the future: Leveraging EHR and patient data to drive better outcomes
The registry of the future: Leveraging EHR and patient data to drive better outcomes Brian J. Kelly, M.D. President, Payer and Provider Solutions, Quintiles Jason Colquitt, VP, IT, Head of RWLPR IT, Global
More informationNEW YORK STATE EXTERNAL APPEAL
NEW YORK STATE EXTERNAL APPEAL You have the right to appeal to the Department of Financial Services (DFS) when your insurer or HMO denies health care services as not medically necessary, experimental/investigational
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationehealth Interoperability State of the Art in Serbia
ehealth Interoperability State of the Art in Serbia Nada Teodosijević ProRec Serbia Western Balkan Summit on ehealth interoperability Ljubljana, 3 rd April 2014 Topics 1. ehealth State of the art in the
More informationFoster care development in Bosnia &Herzegovina
Foster care development in Bosnia &Herzegovina Foster care development in Bosnia & Herzegovina Legal and institutional context of foster care in B&H Strategic documents and policies Features of foster
More informationH. R. ll. To improve access, certainty, and innovation with respect to vaccines. IN THE HOUSE OF REPRESENTATIVES A BILL
F:\M\ELLMER\ELLMER_0.XML TH CONGRESS ST SESSION... (Original Signature of Member) H. R. ll To improve access, certainty, and innovation with respect to vaccines. IN THE HOUSE OF REPRESENTATIVES Mrs. ELLMERS
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationTHE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA
THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA Eriks Mikitis Ministry of Health of the Republic of Latvia Department of Health Care Director General facts, financial resources Ministry
More informationPrevent what is preventable, cure what is curable, provide palliative care for patients in need, and monitor and manage for results.
Proposed PAHO Plan of Action for Cancer Prevention and Control 2008 2015 Prevent what is preventable, cure what is curable, provide palliative care for patients in need, and monitor and manage for results.
More informationLAW OF INSURANCE AGENCY OF BOSNIA AND HERZEGOVINA. Article 1 General Provisions. Article 2 Purpose. Article 3 Creation, Status, Location and Structure
LAW OF INSURANCE AGENCY OF BOSNIA AND HERZEGOVINA Article 1 General Provisions The Law regulates the insurance industry in Bosnia and Herzegovina by ensuring the necessary coordination of the insurance
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationHOW TO ESTABLISH A BUSINESS IN BOSNIA AND HERZEGOVINA
HOW TO ESTABLISH A BUSINESS IN BOSNIA AND HERZEGOVINA TABLE OF CONTENTS STARTING BUSINESS IN BOSNIA AND HERZEGOVINA...5 ESTABLISHEMENT OF BUSINES ENTITIES...5 Registration of business entity...5 Establishment
More informationGreek ehealth Strategy under public consultation
Greek ehealth Strategy under public consultation Mina Boubaki Ministry of Health, IT Department ehealth Network, ehealth Forum Recent relevant Reforms Law 3892/2010 Electronic Recording of Prescription
More informationHEALTH POLICY STATEMENT
Page 1 HEALTH POLICY STATEMENT PREAMBLE The American Nephrology Nurses Association (ANNA) is a national organization of registered nurses practicing in nephrology, which includes but is not limited to
More informationERA-EDTA YOUNG FELLOWSHIP PROGRAMME GENERAL RULES
ERA-EDTA YOUNG FELLOWSHIP PROGRAMME GENERAL RULES PURPOSE The purpose of the ERA-EDTA Young Fellowship Programme is to support basic and clinical research in the field of Nephrology in the ERA-EDTA geographical
More informationThe below tables outline the types of health care services as well as delivery settings:
Assuring Quality Health Care Delivery in Asia Introduction Guk-Hee Suh, PhD, MD, 2014-2016 Chair, ISPOR Asia Consortium Health Service Providers (Clinicians) Committee, and Professor of Psychiatry, Hallym
More informationCurriculum for Nephrology Fellowship
Curriculum for Nephrology Fellowship Consultation: FMLH Service Description of Rotation or Educational Experience This part of the fellowship program in Nephrology provides training and experience such
More informationEURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases
EURORDIS Position Paper on Centres of Expertise and European Reference Networks for Rare Diseases EURORDIS - the European Organisation for Rare Diseases represents 310 rare disease organisations from 34
More informationImplementation of the Regional Office s Country Strategy (2004-2005 period)
WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR EUROPE ORIGINAL: ENGLISH Implementation of the Regional Office s Country Strategy (2004-2005 period) In line with resolution EUR/RC53/R2, requesting the Regional
More informationA Conversation About Medicare Part A, B, C and D
Please take this moment to convert the display to Full Screen A Conversation About Medicare Part A, B, C and D www..com A Conversation About Medicare Part A, B, C and D www.healthcaremedicalpharmaceuticaldirectory.com
More informationStakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Brochure More information from http://www.researchandmarkets.com/reports/1088137/ Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy Description: The drug therapy of acute
More informationFDA STAFF MANUAL GUIDES, VOLUME I ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS OFFICE OF HUMAN RESOURCES
SMG 1117.33 FDA STAFF MANUAL GUIDES, VOLUME I ORGANIZATIONS AND FUNCTIONS FOOD AND DRUG ADMINISTRATION OFFICE OF OPERATIONS OFFICE OF HUMAN RESOURCES DIVISION OF POLICY, PROGRAMS, AND EXECUTIVE RESOURCES
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationNC General Statutes - Chapter 130A Article 7 1
Article 7. Chronic Disease. Part 1. Cancer. 130A-205. Administration of program; rules. (a) The Department shall establish and administer a program for the prevention and detection of cancer and the care
More informationSpeaker Second Plenary Session ELECTRONIC HEALTH RECORDS FOR INFORMED HEALTH CARE IN ASIA- PACIFIC: LEARNING FROM EACH OTHER.
Speaker Second Plenary Session ELECTRONIC HEALTH RECORDS FOR INFORMED HEALTH CARE IN ASIA- PACIFIC: LEARNING FROM EACH OTHER Naoto Kume, PhD Kyoto University Kyoto Prefecture, Japan ISPOR 2014.09.08 11:15am-12:45pm
More informationELITech Group - Product Pipeline Analysis
Brochure More information from http://www.researchandmarkets.com/reports/2351170/ ELITech Group - Product Pipeline Analysis Description: Summary The Elitech Group (Elitech Group) is a medical device company,
More informationIndustry NHS data sharing for collaborative product development
Industry NHS data sharing for collaborative product development Changing strategies in clinical evidence gathering: Are randomised, doubleblinded studies to become extinct? The RCT is not extinct, but
More informationFebruary 19, 2016. RE: Gilead Report Responses. Dear Senators Wyden and Grassley:
February 19, 2016 The Honorable Ron Wyden The Honorable Chuck Grassley Committee on Finance United States Senate 219 Dirksen Senate Office Building Washington, DC 20510-6200 RE: Gilead Report Responses
More informationDoctor of Pharmacy/Master of Public Health Joint Degree Program
Rationale Doctor of Pharmacy/Master of Public Health Joint Degree Program The Master of Public Health (MPH) program is designed to prepare students to become effective leaders, practitioners, researchers,
More informationSOUTH-WEST EUROPE 21
21 SOUTH-WEST EUROPE SOUTH-WEST EUROPE Croatia, Cyprus, Greece, Italy, Malta, Portugal, Slovenia, Spain Access to medicines and medical devices in Mediterranean EU Member States As members of the EU, all
More informationA Real Time Lab for Pan Canadian Innovation Leveraging Canadian Blood Services Model for Better Value to Health care Systems
A Real Time Lab for Pan Canadian Innovation Leveraging Canadian Blood Services Model for Better Value to Health care Systems November 14, 2014 Submission to the Advisory Panel on Health Care Innovation
More informationIMPORTANT INFORMATION Read all pages before signing this form
Kaiser Permanente Medicare Plus (Cost) GROUP/FEHB ENROLLMENT REQUEST FORM Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc. 2101 East Jefferson Street, Rockville, MD 20852 kp.org/medicare
More informationHEALTH CARE DATA IN SAUDI ARABIA: CHALLENGES IN COLLECTING, SHARING, AND APPLYING
HEALTH CARE DATA IN SAUDI ARABIA: CHALLENGES IN COLLECTING, SHARING, AND APPLYING Mohammed Al-Kelya MS, PhD Vice President, ISPOR Saudi Arabia Chapter and Head Quality Management, KAIMRC Riyadh, Kingdom
More informationBrochure More information from http://www.researchandmarkets.com/reports/2860999/
Brochure More information from http://www.researchandmarkets.com/reports/2860999/ Stem Cells: Worldwide Markets for Transplantation and Cord Blood Banking (Projections for Stem Cell Use in Cancer, Alzheimer
More informationMedicare and People with End Stage Renal Disease (ESRD)
FACT SHEET Medicare and People with End Stage Renal Disease (ESRD) (I-002) p. 1 of 7 Medicare and People with End Stage Renal Disease (ESRD) If you have end stage renal disease (ESRD) or permanent kidney
More information2016 Enrollment Form
2016 Enrollment Form White Copy Enrollment Yellow Copy Agent Pink Copy Member Simply Healthcare Scope Lead ID: Black & White Logos Proposed Effective Date of Coverage: Horizontal 2016 Enrollment Request
More informationENROLLMENT APPLICATION. Vista Healthplan Of. Vista South Florida
2009 ENROLLMENT APPLICATION Vista Healthplan Of South Florida, Inc. Vista South Florida Individual Enrollment Request Form To Enroll in Vista Healthplan of South Florida, Inc., Please Provide the Following
More informationRMIP Prescription Plan FAQ's
RMIP Prescription Plan FAQ's A new U.S. Pharmacy Benefit Manager has been selected for January 1, 2015 - CVS/caremark. 1) Why is the RMIP changing to CVS/caremark? The Express Scripts contract ends on
More informationCalifornia Dialysis Council
Michael J. Arnold and Associates, Inc. Legislative Advocates and Consultants Phone: (916) 446-2646 Fax: (916) 446-6095 1127 11th Street, Suite 820, Sacramento, CA 95814 California Dialysis Council LEGISLATIVE
More informationΑthina Triantafyllidi, Director IDIKA S.A
Αthina Triantafyllidi, Director IDIKA S.A The Greek eprescription System is a nationwide widespread web based application for the creation, transmission, dispensing and monitoring of medicine prescriptions
More informationPrescription Drug Benefits
Prescription Drug Benefits This insert will accompany the Medicare- Coordinating Plans Member Handbook for enrollees who are eligible for and have elected these benefits. Important Notice... 1 Using Your
More informationFINLAND ON A ROAD TOWARDS A MODERN LEGAL BIOBANKING INFRASTRUCTURE
Postrefereed, preprint version of the text published at European Journal of Health Law 2013(3)28994. Link to the publisher s website: http://www.brill.com/europeanjournalhealthlaw Sirpa Soini FINLAND ON
More informationFRAMEWORK LAW ON HIGHER EDUCATION IN BOSNIA AND HERZEGOVINA
Pursuant to Article IV.4.a) of the Constitution of Bosnia and Herzegovina, at the 10th session of the House of Representatives, held on June 13th, 2007, and at the 7th session of the House of Peoples,
More informationFRAMEWORK LAW ON HIGHER EDUCATION IN BOSNIA AND HERZEGOVINA
Pursuant to Article IV.4.a) of the Constitution of Bosnia and Herzegovina, at the 10th session of the House of Representatives, held on June 13th, 2007, and at the 7th session of the House of Peoples,
More informationMULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs
More informationThe objectives of the Sri Lankan National Medicinal Drug Policy are
NATIONAL MEDICINAL DRUG POLICY FOR SRI LANKA Preamble Sri Lanka had a partly written Drug Policy from the 1960s. It was written as elements of a policy, beginning from selection of drugs for the government
More informationHow To Get A Health Care Plan In Colombia
3rd ISPOR Latin America September 2011 México City, México Jorge Augusto Diaz Rojas, MSc, PhD candidate Associate professor Universidad Nacional de Colombia, Bogotá, D.C.,Colombia. Population Projection
More informationReimbursement for Medical Products: Ensuring Marketplace
Reimbursement for Medical Products: Ensuring Marketplace Success by Securing Coverage and Payment Christopher J. Panarites, Ph.D. Director, Endovascular Products Health Economics and Outcomes Research
More informationWilson Disease Research and Care. Looking Forward Ann Arbor, Michigan September 6, 2014 Fred Askari MD, PhD
Wilson Disease Research and Care Looking Forward Ann Arbor, Michigan September 6, 2014 Fred Askari MD, PhD The Future is Bright Improved Access to Care Improved Diagnostics Earlier Diagnosis New Treatments
More informationClinical decision support based on practice guidelines: a business case on prostate cancer treatment
Clinical decision support based on practice guidelines: a business case on prostate cancer treatment Denis PIERRE Denis PIERRE pierre@normind.com Ph. +33 (0)4 67 13 01 77 pierre@normind.com Ph. +33 (0)4
More informationElements for optimising Orphan drug development industry perspective
Elements for optimising Orphan drug development industry perspective IRDiRC Conference, Dublin, 17 April 2013 Wills Hughes-Wilson, Vice President External Affairs, Chief Patient Access Officer, Sobi With
More informationYour Pharmacy Benefit: Make it Work for You!
Your Pharmacy Benefit: Make it Work for You! www.yourpharmacybenefit.org Table of Contents Choose Your Plan.............................................2 Steps in Choosing Your Pharmacy Benefits.........................
More informationComments on Information Collection Request for Healthcare Common Procedure Coding System
September 17, 2007 Reference No.: FASC07061 Bonnie L. Harkless Division of Regulations Development Office of Strategic Operations and Regulatory Affairs Centers for Medicare and Medicaid Services Room
More informationEPOC Taxonomy topics list
EPOC Taxonomy topics list Delivery Arrangements Changes in how, when and where healthcare is organized and delivered, and who delivers healthcare. How and when care is delivered Group versus individual
More informationEnrollment Application Instructions 2015 Plan Year
Enrollment Application Instructions 2015 Plan Year Please read before completing your enrollment request form. You are eligible to join Care N Care Health Plan(s) HMO if: You are entitled to Medicare Part
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationNational Report regarding the Bologna Process implementation 2009-2012. Bosnia and Herzegovina
National Report regarding the Bologna Process implementation 2009-2012 Bosnia and Herzegovina 1 Part 1.0 BFUG Data Collection: administrative information For which country do you fill in the questionnaire?
More informationGastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/
Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationRenal Cell Carcinoma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2365661/ Renal Cell Carcinoma (Event Driven) Description: The Renal Cell Carcinoma market is highly lucrative. We anticipate that
More informationVNS CHOICE: Managing Complex Care Needs for the Frail Elderly of New York City. Roberta Brill Vice President, VNS Health Plans
VNS CHOICE: Managing Complex Care Needs for the Frail Elderly of New York City Roberta Brill Vice President, VNS Health Plans VNS CHOICE Organization Subsidiary of the Visiting Nurse Service of New York
More informationComments on the 21 st Century Cures: Digital Health Care
Comments on the 21 st Century Cures: Digital Health Care July 22, 2014 The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide input to the House Energy
More informationNational Health Insurance Policy 2013
National Health Insurance Policy 2013 1. Background The Interim Constitution of Nepal 2007 provides for free basic health care as a fundamental right of citizens. Accordingly, the Government of Nepal has
More informationCoventry Health and Life Insurance Company PPO Schedule of Benefits
State(s) of Issue: Oklahoma PPO Plan: OI08C30050 30 Coventry Health and Life Insurance Company PPO Schedule of Benefits Covered Services Contract Year Deductible For All Eligible Expenses (unless otherwise
More informationTargeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute
Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information
More information